Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters
| Autor: | John D. Lambris, Hui Chen, Ranillo R.G. Resuello, Edimara S. Reis, Daniel Ricklin, Robert A. DeAngelis |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_treatment
Immunology Inflammation Article Mediator Renal Dialysis medicine Animals Immunology and Allergy Complement Activation Survival rate Dialysis business.industry Micropore Filters Complement C3 Hematology Interleukin-10 Complement system Macaca fascicularis Interleukin 10 Cytokine Models Animal Hemodialysis medicine.symptom Peptides business |
| Zdroj: | Immunobiology. 220:476-482 |
| ISSN: | 0171-2985 |
| DOI: | 10.1016/j.imbio.2014.10.026 |
| Popis: | Approximately 350,000 individuals in the United States rely on maintenance hemodialysis treatment because of end-stage renal disease. Despite improvements in dialysis technology, the mortality rate for patients treated with maintenance dialysis is still exceptionally high, with a 5-year survival rate of only 35%. Many patients succumb to conditions resulting at least in part from the chronic induction of inflammation. Among the triggers of inflammation, the complement system is of particular importance, being a well-appreciated mediator of inflammatory processes that is involved in many pathologic states. Here we used a refined pre-clinical model of hemodialysis in cynomolgus monkeys to confirm that even modern, polymer-based hemodialysis filters activate complement and to evaluate the potential of Cp40, a peptidic C3 inhibitor, to attenuate hemodialysis-induced complement activation. Our data show marked induction of complement activation even after only a single session of hemodialysis. Importantly, complete inhibition of complement activation was achieved in response to two distinct Cp40 treatment regimens. Further, we show that application of Cp40 during hemodialysis resulted in increased levels of the anti-inflammatory cytokine IL-10, indicating that Cp40 may be a potent and cost-effective treatment option for attenuating chronic inflammatory conditions in dialysis-dependent patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect